Prostate cancer (PCa) is the most frequent malignancy and the second leading cause of cancer-related male death. Currently, markers fail in providing an effective patient stratification. Lethal cases receive new therapies once they have failed local and hormonal treatment. The mammalian macromolecular complex, as CTLH E3-ubiquitin ligase, characterized by well conserved CTLH domain showing an ubiquitin ligase activity increasing cell radiosensitivity in prostate cancer. This suggests that the CTLH Complex, through its main protein RanBP9, is potentially involved in the PCa tumorigenesis. The aim of this project is to investigate the role of RanBP9 in PCa progression and to address the basis for a novel therapy response prediction.